Karyopharm Therapeutics Inc. (KPTI)
NASDAQ: KPTI · Real-Time Price · USD
2.000
+0.050 (2.56%)
Aug 7, 2026, 1:14 PM EDT - Market open
Karyopharm Therapeutics Revenue
Karyopharm Therapeutics had revenue of $35.07M in the quarter ending March 31, 2026, with 16.83% growth. This brings the company's revenue in the last twelve months to $151.12M, up 6.33% year-over-year. In the year 2025, Karyopharm Therapeutics had annual revenue of $146.07M with 0.57% growth.
Revenue (ttm)
$151.12M
Revenue Growth
+6.33%
P/S Ratio
0.29
Revenue / Employee
$662,798
Employees
228
Market Cap
45.33M
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 146.07M | 830.00K | 0.57% |
| Dec 31, 2024 | 145.24M | -796.00K | -0.55% |
| Dec 31, 2023 | 146.03M | -11.04M | -7.03% |
| Dec 31, 2022 | 157.07M | -52.75M | -25.14% |
| Dec 31, 2021 | 209.82M | 101.73M | 94.12% |
| Dec 31, 2020 | 108.09M | 67.19M | 164.31% |
| Dec 31, 2019 | 40.89M | 10.56M | 34.80% |
| Dec 31, 2018 | 30.34M | 28.73M | 1,790.09% |
| Dec 31, 2017 | 1.61M | 1.45M | 942.21% |
| Dec 31, 2016 | 154.00K | -96.00K | -38.40% |
| Dec 31, 2015 | 250.00K | 21.00K | 9.17% |
| Dec 31, 2014 | 229.00K | -158.00K | -40.83% |
| Dec 31, 2013 | 387.00K | -247.00K | -38.96% |
| Dec 31, 2012 | 634.00K | 482.00K | 317.11% |
| Dec 31, 2011 | 152.00K | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| Metagenomi Therapeutics | 22.33M |
| Radiopharm Theranostics | 10.86M |
| Immutep | 5.28M |
| Seres Therapeutics | 1.88M |
| Mereo BioPharma Group | 500.00K |
| aTyr Pharma | 190.00K |
| Impact BioMedical | 39.00K |
KPTI News
- 3 days ago - Karyopharm Therapeutics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) - PRNewsWire
- 7 days ago - Karyopharm price target lowered to $11 from $14 at Jefferies - TheFly
- 7 days ago - Karyopharm price target lowered to $7 from $16 at Piper Sandler - TheFly
- 7 days ago - Karyopharm downgraded to Neutral from Buy at H.C. Wainwright - TheFly
- 7 days ago - Karyopharm downgraded to Neutral from Outperform at Baird - TheFly
- 7 days ago - Karyopharm down 69% after XPORT-EC-042 trial did not meet primary endpoint - TheFly
- 7 days ago - Karyopharm to submit sNDA for selinexor plus ruxolitinib - TheFly
- 7 days ago - Karyopharm’s endometrial cancer candidate did not meet Phase 3 primary endpoint - TheFly